Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study-Reference-Cited by-同舟云学术

Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study

Published:2024-02-09 Issue: Volume: Page:
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:

Author:

Yeh Julian G.¹²³^ORCID,Newsome Philip N.¹²³^ORCID

Affiliation:

1. Department of Liver Medicine, Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

2. National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK

3. Department of Immunology and Immunotherapy, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference11 articles.

1. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review;Mantovani;Lancet Gastroenterol Hepatol,2022

2. GLP-1 RAs and SGLT-2 inhibitors for insulin resistance in nonalcoholic fatty liver disease: Systematic review and network meta-analysis;Yan;Front Endocrinol (Lausanne),2022

3. Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis;Borodavkin;Diabetes Obes Metab,2022

4. Thiazolidinediones and glucagon‐like peptide‐1 receptor agonists and the risk of nonalcoholic fatty liver disease: A cohort study;Van Dalem;Hepatology,2021

5. American Association of Clinical Endocrinology Consensus Statement: Comprehensive type 2 diabetes management algorithm—2023 update;Samson;Endocr Pract,2023